ESMO Advanced Course on Precision Oncology in Oncogene-Addicted NSCLC: EGFR, ALK, ROS, MET

PROGRAMME

ESMO ADVANCED COURSE

BARCELONA SPAIN
23-24 JUNE 2023

Co-Chairs
Sabina Berezowska, Switzerland
Jürgen Wolf, Germany
ESMO ADVANCED COURSE PROGRAMME

PRECISION ONCOLOGY IN ONCOGENE-ADDICTED NSCLC: EGFR, ALK, ROS, MET

Barcelona, Spain
23-24 June 2023

CO-CHAIRS
Sabina Berezowska, Switzerland
Jürgen Wolf, Germany

SPEAKERS
Bettina Bisig, Switzerland
Anna Kron, Germany
Fernando López-Ríos, Spain
Julien Mazières, France
Laura Mezquita, Spain
Silvia Novello, Italy
Egbert F. Smit, Netherlands
Verena Tischler, Germany

LEARNING OBJECTIVES

• To understand the biology of specific oncogene addicted NSCLC and the rationale for targeted treatment
• To review the targeted treatment strategies, including current approvals and ongoing trials, in patients with oncogene addicted NSCLC
• To learn about the best current practice regarding testing methodology and get an outlook on future developments
• To improve interdisciplinary collaboration between oncology and pathology by understanding individual challenges in testing and treatment
• To understand health-economical aspects of targeted treatment in NSCLC

ACCREDITATION

The programme of this event has been accredited with 8 ESMO-MORA category 1 points.
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from

Janssen Oncology
Roche
Thermo Fisher Scientific

ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4, 6900 Lugano, Switzerland
Email: courses@esmo.org
www.esmo.org
Friday, 23 June 2023

09:00-09:10 Welcome and introduction
10’ Welcome and Learning Objectives Introduction
Sabina Berezowska, CH and Jürgen Wolf, DE

09:10-10:55 Session 1 – Molecular target / Family of targets – EGFR
Chairs: Julien Mazières, FR and Verena Tischler, DE
15’ Biology of the target / biomarker (function and roles in normal and tumour tissue homeostasis)
Fernando López-Ríos, ES
5’ Q&A

20’ Update on the clinical efficacy of approved targeted agents: Formal indications, efficacy and toxicity
Egbert F. Smit, NL
5’ Q&A

20’ Testing for the target / biomarker (assays, technicalities and practicalities, challenges for interpretation)
Fernando López-Ríos, ES
10’ Q&A

20’ A clinicopathological case presented and discussed by a Molecular Tumour Board
Egbert F. Smit, NL
10’ Q&A

10:55-11:25 Coffee break

11:25-13:10 Session 2 – Molecular target / Family of targets – ALK
Chairs: Verena Tischler, DE and Jürgen Wolf, DE
15’ Biology of the target / biomarker (function and roles in normal and tumour tissue homeostasis)
Sabina Berezowska, CH
5’ Q&A

20’ Update on the clinical efficacy of approved targeted agents: Formal indications, efficacy and toxicity
Silvia Novello, IT
5’ Q&A

20’ Testing for the target / biomarker (assays, technicalities and practicalities, challenges for interpretation)
Bettina Bisig, CH
10’ Q&A

20’ A clinicopathological case presented and discussed by a Molecular Tumour Board
Laura Mezquita, ES
10’ Q&A

13:10-14:00 Lunch

14:10-15:55 Session 3 – Molecular target / Family of targets – ROS
Chairs: Fernando López-Ríos, ES and Jürgen Wolf, DE
15’ Biology of the target / biomarker (function and roles in normal and tumour tissue homeostasis)
Sabina Berezowska, CH
5’ Q&A
20’ Update on the clinical efficacy of approved targeted agents: Formal indications, efficacy and toxicity
Julien Mazières, FR
5’ Q&A

20’ Testing for the target / biomarker (assays, technicalities and practicalities, challenges for interpretation)
Bettina Bisig, CH
10’ Q&A

20’ A clinicopathological case presented and discussed by a Molecular Tumour Board
Julien Mazières, FR
10’ Q&A

19:30 Networking Dinner

Saturday, 24 June 2023

09:00-09:40 Session 4 – Precision oncology from the perspective of health economics
Chairs: Sabina Berezowska, CH and Julien Mazières, FR

30’ Value / health economics of testing and targeting (incl. MCBS, ESCAT actionability, RWD)
Anna Kron, DE
10’ Q&A

09:40-11:55 Session 5 – Molecular target / Family of targets – MET
Chairs: Bettina Bisig, CH and Laura Mezquita, ES

15’ Biology of the target / biomarker (function and roles in normal and tumour tissue homeostasis)
Verena Tischler, DE
5’ Q&A

20’ Update on the clinical efficacy of approved targeted agents: Formal indications, efficacy and toxicity
Jürgen Wolf, DE
5’ Q&A

10:25-10:55 Coffee break

20’ Testing for the target / biomarker (assays, technicalities and practicalities, challenges for interpretation)
Verena Tischler, DE
10’ Q&A

20’ A clinicopathological case presented and discussed by a Molecular Tumour Board
Jürgen Wolf, DE
10’ Q&A

11:55-12:05 Synthesis and wrap-up
Sabina Berezowska, CH and Jürgen Wolf, DE

12:05-13:05 Lunch